Immunomodulation for maxillofacial reconstructive surgery
Abstract Immunomodulation is a technique for the modulation of immune responses against graft material to improve surgical success rates. The main target cell for the immunomodulation is a macrophage because it is the reaction site of the graft and controls the healing process. Macrophages can be classified into M1 and M2 types. Most immunomodulation techniques focus on the rapid differentiation of M2-type macrophage. An M2 inducer, 4-hexylresorcinol, has been recently identified and is used for bone grafts and dental implant coatings..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Maxillofacial plastic and reconstructive surgery - 42(2020), 1 vom: 05. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Seong-Gon [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1186/s40902-020-00249-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR039011216 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR039011216 | ||
| 003 | DE-627 | ||
| 005 | 20230519162144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40902-020-00249-4 |2 doi | |
| 035 | |a (DE-627)SPR039011216 | ||
| 035 | |a (SPR)s40902-020-00249-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Kim, Seong-Gon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunomodulation for maxillofacial reconstructive surgery |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Immunomodulation is a technique for the modulation of immune responses against graft material to improve surgical success rates. The main target cell for the immunomodulation is a macrophage because it is the reaction site of the graft and controls the healing process. Macrophages can be classified into M1 and M2 types. Most immunomodulation techniques focus on the rapid differentiation of M2-type macrophage. An M2 inducer, 4-hexylresorcinol, has been recently identified and is used for bone grafts and dental implant coatings. | ||
| 650 | 4 | |a Immunomodulation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Macrophage |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Wound healing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a 4-Hexylresorcinol |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Maxillofacial plastic and reconstructive surgery |d Berlin : SpringerOpen, 2014 |g 42(2020), 1 vom: 05. März |w (DE-627)SPR037984039 |w (DE-600)2815852-0 |x 2288-8586 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2020 |g number:1 |g day:05 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40902-020-00249-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2020 |e 1 |b 05 |c 03 | ||